Mode
Text Size
Log in / Sign up
N/A N=29 Treatment

Auricular Acupuncture For The Treatment Of Non-Epileptic Seizures

Convulsion, Non-Epileptic

Enrolled (actual)
29
Serious AEs
0.0%
Results posted
Dec 2017
Primary outcome: Primary: Completion Rate of Auricular Acupuncture in Patients With NES — 15 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Auricular acupuncture (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Denver Health and Hospital Authority
Primary completion
Jan 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Completion Rate of Auricular Acupuncture in Patients With NES
15
SECONDARY
Adverse Events
5; 4; 6; 9; 1; 1
SECONDARY
Compliance Rates of NES Seizure Diary
90
SECONDARY
Trend for Auricular Acupuncture to Reduce NES Frequency
15; 13; 16

Summary

This feasibility study will determine the tolerability of auricular acupuncture, compliance with self-reported seizure tracking, and the quality of a proposed sham acupuncture protocol to inform the design of a large, multi-center, placebo-controlled, double-blind study to demonstrate the therapeutic effect of auricular acupuncture for the treatment of Non-Epileptic Seizures.

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of non-epileptic seizures, confirmed by ictal routine EEG or ictal video EEG
  • Age 18-75
  • Ability to provide informed consent and comply with study activities
  • > 2 NES per month

Exclusion Criteria

  • Serious mental health disorder or medical or neurological illness (requiring systemic treatment and/or hospitalization) until subject either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 30 days prior to study entry.
  • Pregnancy, self-discovered pregnancy, lactation, or plans to become pregnant.
  • Inability to distinguish between NES and comorbid epileptic seizures.
  • Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  • Inability or unwillingness of subject or legal guardian/representative to give written informed con-sent.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01919307). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search